Solifenacin succinate
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder
Trial Timeline
— → —
NCT ID
NCT00189800About Solifenacin succinate
Solifenacin succinate is a phase 3 stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT00189800. Target conditions include Overactive Bladder.
What happened to similar drugs?
20 of 20 similar drugs in Overactive Bladder were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189800 | Phase 3 | Completed |
| NCT01981954 | Phase 3 | Completed |
| NCT01565694 | Phase 3 | Completed |
| NCT00909428 | Approved | Completed |
| NCT00337558 | Approved | Completed |
| NCT00463541 | Phase 3 | Completed |
| NCT00454740 | Phase 3 | Completed |
Competing Products
20 competing products in Overactive Bladder